Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Active-Controlled, Open-Label Study of Yttrium [90Y] Microsphere Injection in Combination With Camrelizumab and/or Apatinib and Yttrium [90Y] Microsphere Injection Alone Versus cTACE in the Treatment of HCC

NCT07334483 is registered in ClinicalTrials.gov with GrandPharma (China) Co., Ltd. as lead sponsor.

NCT NCT07334483
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07334483 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Active-Controlled, Open-Label Study of Yttrium [90Y] Microsphere Injection in Combination With Camrelizumab and/or Apatinib and Yttrium [90Y] Microsphere Injection Alone Versus cTACE in the Treatment of HCC
Lead sponsor
GrandPharma (China) Co., Ltd.
Phase
Phase 2
Overall status
Recruiting
Start date
August 22, 2025
Completion date
December 30, 2027
Enrollment
120 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

hcc